Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand Graham Gulbransen, MBChB, FAChAM, FRNZCGP1*, William Xu2, Bruce Arroll, MBChB, PhD, FRNZCG BJGP Open, 2020, 1-8 DOI : 10.3399/bjgpopen20X101010 Abstract Background : Cannabidiol (CBD) is the non- euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear. Aim : To review the changes in self- reported quality of life measurements, drug tolerability, and dose- dependent relationships in patients prescribed CBD oil for various conditions at a single institution. Design & setting : An [...]
Lire la suiteMedical use of cannabis products. Lessons to be learned from Israel and Canada J. Ablin, P.A. Ste-Marie, M. Schäfer, W. Häuser, M.-A. Fitzcharles Der Schmerz, 2016, 1-10 DOI 10.1007/s00482-015-0083-4 © Deutsche Schmerzgesellschaft e.V. Published by Springer-Verlag Berlin Heidelberg - all rights reserved 2015 Abstract Introduction : The German government intends to reduce the barriers for the medical use of cannabis products. A discussion on the indications and contraindications of the medical use of cannabis and on the changes of the regulatory framework has already begun in Germany. It is useful to draw from the experiences of other countries with a more liberal medical use of cannabis. Methods [...]
Lire la suite